HomeCompareCSPHF vs EQR

CSPHF vs EQR: Dividend Comparison 2026

CSPHF yields 198.02% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPHF wins by $112.66M in total portfolio value
10 years
CSPHF
CSPHF
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CSPHF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CSPHF vs EQR

📍 CSPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPHFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPHF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPHF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPHF
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, CSPHF beats the other by $48,051,078.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPHF + EQR for your $10,000?

CSPHF: 50%EQR: 50%
100% EQR50/50100% CSPHF
Portfolio after 10yr
$56.37M
Annual income
$28,269,159.62/yr
Blended yield
50.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CSPHF
No analyst data
Altman Z
9.2
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPHF buys
0
EQR buys
0
No recent congressional trades found for CSPHF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPHFEQR
Forward yield198.02%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$112.70M$40.5K
Annual income after 10y$56,534,499.65$3,819.61
Total dividends collected$106.15M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CSPHF vs EQR ($10,000, DRIP)

YearCSPHF PortfolioCSPHF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$30,502$19,801.98$11,248$547.57+$19.3KCSPHF
2$89,086$56,448.56$12,701$666.53+$76.4KCSPHF
3$249,403$154,080.96$14,405$814.59+$235.0KCSPHF
4$670,003$403,142.26$16,413$999.84+$653.6KCSPHF
5$1,729,066$1,012,162.66$18,795$1,232.92+$1.71MCSPHF
6$4,291,289$2,441,188.37$21,639$1,527.95+$4.27MCSPHF
7$10,253,990$5,662,310.92$25,057$1,903.80+$10.23MCSPHF
8$23,616,660$12,644,890.45$29,197$2,385.87+$23.59MCSPHF
9$52,487,868$27,218,041.68$34,250$3,008.70+$52.45MCSPHF
10$112,696,518$56,534,499.65$40,467$3,819.61+$112.66MCSPHF

CSPHF vs EQR: Complete Analysis 2026

CSPHFStock

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Full CSPHF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CSPHF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPHF vs SCHDCSPHF vs JEPICSPHF vs OCSPHF vs KOCSPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.